10-K/A: Arcadia Biosciences Files Amendment No. 1 to Form 10-K, Providing Detailed Information on Directors, Executive Compensation, and Corporate Governance

Arcadia Biosciences files an amendment to its 2024 annual report to include previously omitted information regarding directors, executive compensation, and corporate governance.

Summary

• Arcadia Biosciences filed Amendment No. 1 on Form 10-K/A to its Annual Report on Form 10-K for the year ended December 31, 2024.
• The amendment includes information required by Part III of Form 10-K, which was previously omitted from the original filing.
• The information includes details about directors, executive officers, corporate governance, executive compensation, security ownership, related party transactions, and principal accountant fees.
• As of April 23, 2025, the registrant had 1,367,040 shares of common stock outstanding, $0.001 par value per share.
• Thomas J. Schaefer was appointed President and CEO in July 2024, with an annual base salary of $260,000.
• Mark Kawakami was appointed CFO in July 2024, with an annual base salary of $212,063.
• The aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant as of June 30, 2024, was approximately $4,184,025 (based on the closing price of $3.15 on June 28, 2024 on the NASDAQ Capital Market).

Sentiment

Score: 6

Explanation: The document is primarily factual and descriptive, with a neutral tone. The inclusion of executive departures and severance payments introduces a slightly negative element, while the focus on corporate governance and compliance is viewed positively.

Positives

• The company has a Code of Business Conduct and Ethics applicable to all employees, officers, and directors.
• The company has an insider trading policy designed to promote compliance with U.S. insider trading laws.
• The Board of Directors has determined that a majority of the directors are independent.
• The audit committee is comprised of independent and financially literate members.
• The company has severance and change in control agreements in place with its executive officers.

Negatives

• Former executives Stanley E. Jacot, Jr. and Laura Pitlik resigned, resulting in severance payments.
• Certain stockholders have beneficial ownership limited to 4.99% due to warrant and investment option terms.
• The company has a history of losses and negative cash flow.

Risks

• Failure to comply with insider trading laws could result in significant penalties.
• The company's future performance is subject to various risks and uncertainties.
• The proposed transaction with Roosevelt Resources is subject to certain conditions and may not be completed.

Future Outlook

At or before the Closing, Arcadia expects to enter into an amendment of Mr. Schaefers and Mr. Kawakamis employment agreement and severance and change in control agreement to provide, among other things, that effective upon the Closing and the effective time of the Exchange, (i) Mr. Schaefer will no longer be President and Chief Executive Officer of Arcadia and will resign as a director of Arcadia but will remain an employee of the combined company, (ii) Mr. Kawakami will no longer be Chief Financial Officer of Arcadia but will remain an employee of the combined company, and (ii) that such changes do not constitute good reason as defined in such persons severance and change in control agreement.

Industry Context

The document provides insight into the executive compensation and corporate governance practices of a publicly traded company in the biotechnology sector. These practices are generally aligned with industry standards for companies of similar size and stage of development.

Comparison to Industry Standards

• Executive compensation packages, including salary, bonus, and equity awards, are generally in line with those offered by other small-cap biotechnology companies.
• The composition of the Board of Directors, with a majority of independent directors, aligns with corporate governance best practices.
• The company's insider trading policy and code of ethics are standard for publicly traded companies.
• The audit committee's responsibilities and composition are consistent with SEC and Nasdaq requirements.

Management Changes

Corporate Governance

Related Party Transactions

• On March 6, 2023, we sold to certain institutional and accredited investors (i) 165,500 shares of our common stock (the 2023 Shares) at a purchase price per share of $9.00, (ii) pre-funded warrants (the Pre-Funded Warrants) to purchase up to 500,834 shares of our common stock; (iii) Series A preferred investment options (the Series A Investment Options) to purchase up to a total of 666,334 shares of our common stock and (iv) Series B preferred investment options (the Series B Investment Options, and together with the Series A Investment Options, the Investment Options) to purchase up to a total of 666,334 shares of our common stock.
• Pursuant to this transaction, (i) Armistice Capital Master Fund Ltd. purchased 82,500 shares of common stock, 250,834 Pre-Funded Warrants, 333,334 Series A Investment Options and 333,334 Series B Investment Options, (ii) Sabby Volatility Warrant Master Fund, Ltd. purchased 250,000 Pre-Funded Warrants, 250,000 Series A Investment Options and 250,000 Series B Investment Options, and (iii) Altium Growth Fund Ltd. purchased 83,000 shares of common stock, 83,000 Series A Investment Options and 83,000 Series B Investment Options.

Stakeholder Impact

• Shareholders: The amendment provides greater transparency regarding executive compensation and corporate governance.
• Employees: Changes in executive leadership and potential restructuring may impact employee morale and job security.
• Customers: The company's strategic direction and product development may be affected by the proposed transaction with Roosevelt Resources.
• Suppliers: The company's purchasing patterns and payment terms may be influenced by the company's financial performance and strategic initiatives.

Next Steps

• The company expects to close the transactions contemplated by the Exchange Agreement.
• Arcadia expects to enter into an amendment of Mr. Schaefers and Mr. Kawakamis employment agreement and severance and change in control agreement.

Key Dates

Keywords

executive compensation, corporate governance, directors, officers, insider trading, stock options, beneficial ownership, audit fees, related party transactions, Arcadia Biosciences